机器人辅助根治性膀胱切除术联合体内尿流改道与开放根治性膀胱切除术治疗膀胱癌的疗效比较
这项真实世界单中心研究纳入2014至2023年连续接受机器人辅助根治性膀胱切除术联合体内尿流改道(RARC+ICUD,n=228)或开放根治性膀胱切除术(ORC,n=88)的膀胱癌患者,比较围手术期、肿瘤学及输尿管肠吻合口狭窄结局。RARC+ICUD组围手术期结局更优且淋巴结清扫数目更高,两组肿瘤学及狭窄结局无显著差异。
要点
- RARC+ICUD较ORC降低大出血、围手术期输血、90天重大并发症及初始住院时间延长的风险。
- RARC+ICUD组淋巴结清扫数目更高(OR 3.35,95%CI 1.83-6.30;P<0.001)。
- 中位随访42.3个月,两组无复发生存、肿瘤特异性生存、总生存及无输尿管肠吻合口狭窄生存均无显著差异。
核心结论
- 真实世界研究支持RARC+ICUD相较ORC用于膀胱癌的有效性,围手术期结局总体更优,肿瘤学结局除淋巴结数目更高外相似,输尿管肠吻合口狭窄结局相似。
研究设计与样本
- 真实世界单中心研究,纳入2014至2023年在本机构连续接受RARC+ICUD或ORC的膀胱癌患者,共316例,其中RARC+ICUD组228例(72.2%),ORC组88例(27.8%)。
- 采用单因素和多因素logistic回归及Cox回归分析,计算比值比(OR)和风险比(HR)及其95%置信区间(CI)。
主要发现
- RARC+ICUD vs ORC:大出血风险OR 0.10(95%CI 0.04-0.23;P<0.001),围手术期输血OR 0.30(95%CI 0.16-0.57;P<0.001),90天重大并发症OR 0.56(95%CI 0.29-0.99;P=0.04),初始住院时间延长OR 0.20(95%CI 0.09-0.35;P<0.001)。
- RARC+ICUD vs ORC:术后90天内存活且院外天数更多,OR 2.56(95%CI 1.46-4.6;P<0.01)。
- RARC+ICUD vs ORC:淋巴结计数更高,OR 3.35(95%CI 1.83-6.30;P<0.001)。
- 中位随访42.3个月(四分位距16.4-73.8),RARC+ICUD vs ORC:无复发生存HR 0.72(95%CI 0.49-1.07;P=0.1),肿瘤特异性生存HR 0.69(95%CI 0.43-1.10;P=0.1),总生存HR 0.76(95%CI 0.47-1.20;P=0.3),无输尿管肠吻合口狭窄生存HR 1.18(95%CI 0.62-2.25;P=0.6),均无显著差异。
临床怎么用
- 作者认为真实世界研究支持RARC+ICUD相较ORC用于膀胱癌的有效性。
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To assess the comparative effectiveness of robot-assisted radical cystectomy (RARC) with intracorporeal urinary diversion (ICUD) vs open radical cystectomy (ORC) for bladder cancer (BC). PATIENTS AND METHODS: We conducted a real-life monocentric study including all consecutive patients who underwent RARC with ICUD or ORC for BC at our institution from 2014 to 2023. Uni- and multivariable logistic and Cox regression analyses were used to compare perioperative, oncological and stricture outcomes between both groups by calculating odds (ORs) and hazard (HRs) ratios with their corresponding 95% confidence intervals (CIs), respectively. RESULTS: Overall, 316 patients underwent either RARC with ICUD (n = 228 [72.2%]) or ORC (n = 88 [27.8%]). The perioperative benefits of RARC vs ORC included decreased risks of major blood loss (OR 0.10, 95% CI 0.04-0.23; P < 0.001), perioperative transfusion (OR 0.30, 95% CI 0.16-0.57; P < 0.001), 90-day major complications (OR 0.56, 95% CI 0.29-0.99; P = 0.04), and prolonged initial length of hospital stay (OR 0.20, 95% CI 0.09-0.35; P < 0.001), as well as more days alive and out of the hospital within 90 days of surgery (OR 2.56, 95% CI 1.46-4.6; P < 0.01). In addition, the use of RARC vs ORC was associated with a higher lymph node (LN) count (OR 3.35, 95% CI 1.83-6.30; P < 0.001), while there was no significant difference in recurrence-free (HR 0.72, 95% CI 0.49-1.07; P = 0.1), cancer-specific (HR 0.69, 95% CI 0.43-1.10; P = 0.1), overall (HR 0.76, 95% CI 0.47-1.20; P = 0.3) and uretero-ileal stricture-free (HR 1.18, 95% CI 0.62-2.25; P = 0.6) survival between both groups after a median (interquartile range) follow-up of 42.3 (16.4-73.8) months. CONCLUSION: Our real-world study supports the effectiveness of RARC with ICUD vs ORC for BC. We generally observed better perioperative outcomes, as well as similar oncological-except for higher LN count-and uretero-ileal stricture outcomes after RARC with ICUD vs ORC.
引用
- Gabriel PE, Pinar U, Lenfant L, et al. Comparative effectiveness of robot-assisted radical cystectomy with intracorporeal urinary diversion vs open radical cystectomy for bladder cancer. BJU Int. 2024. PMID: 39433445. doi:10.1111/bju.16565
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。